A MULTICENTRE study, presented at EBMT 2025 Annual Meeting, sheds light on the outcomes of allogeneic hematopoietic cell transplantation (HCT) in patients with MDS/AML (Myelodysplastic Syndromes/Acute Myeloid Leukaemia). This abstract was recognised as one of the ‘Best Young Abstract Awards’ for outstanding poster presentations.
The study involved 228 patients, including 79 with MDS/AML and 149 with AML. The findings, based on a median follow-up of 33 months, revealed key insights into the prognostic factors influencing transplantation outcomes. It focused on four MDS/AML subcategories: mutated TP53, myelodysplasia-related (MR) gene mutations, MR cytogenetic abnormalities, and not otherwise specified (NOS).
Among these, patients with MR gene mutations and NOS had significantly better 2-year progression-free survival (PFS) compared to those with mutated TP53, which was 20.8%. Stratifying by the revised International Prognostic Scoring System (IPSS-R), very-high-risk MDS/AML patients had a significantly worse PFS and higher relapse rates.
The study highlighted that in patients with MDS/AML, the NOS subcategory might benefit from allogeneic transplantation, while those with mutated TP53 or MR genetic abnormalities required intensive monitoring post-transplantation. Additionally, the researchers concluded that the IPSS-R was better applicable than the ELN criteria for predicting transplant outcomes of MDS/AML patients.
Reference
Ru Y et al. Abstract: B220. Presented at EBMT 2025 Annual Meeting;31 Mar -2 April; Florence, Italy.
